Dynlt3 — Dynein Light Chain Tctex Type 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Dynlt3 — Dynein Light Chain Tctex Type 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@rao2009]
Dynlt3 — Dynein Light Chain Tctex Type 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Introduction
Dynlt3 — Dynein Light Chain Tctex Type 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@rao2009]
DYNLT3 encodes a dynein light chain protein that is part of the cytoplasmic dynein motor complex. Like DYNLT1, DYNLT3 can form homodimers and may have distinct cargo binding specificities compared to other dynein light chains. DYNLT3 is expressed in [neurons](/entities/neurons) and has been implicated in the transport of signaling molecules and organelles. While its specific neuronal functions are less characterized than DYNLT1, DYNLT3 is thought to play complementary roles in dynein-mediated transport. Studies suggest alterations in dynein function may contribute to the pathogenesis of spinal muscular atrophy and Huntington's disease.
Expressed in tissues with high transport requirements.
Disease Associations
| Disease | Role | Mechanism | |---------|------|-----------| | Alzheimer's Disease | Risk/Progression | Various mechanisms depending on gene function | | Parkinson's Disease | Risk/Progression | Various mechanisms depending on gene function | | Amyotrophic Lateral Sclerosis | Risk/Progression | Various mechanisms depending on gene function |
Therapeutic Implications
Targeting DYNLT3 has therapeutic potential in neurodegenerative diseases through:
Gene therapy approaches for loss-of-function variants
Small molecule modulators of protein function
Protein supplementation strategies
Key Publications
King SM, et al. (1998). "Dynein light chains." Biochim Biophys Acta. PMID: 9602162(https://pubmed.ncbi.nlm.nih.gov/9602162/)
Hafezparast M, et al. (2003). "Dynein and neurodegeneration." EMBO Rep. PMID: 12947150(https://pubmed.ncbi.nlm.nih.gov/12947150/)
Rao MV, et al. (2009). "Dynein light chains in neuronal function." J Neurosci Res. PMID: 19224580(https://pubmed.ncbi.nlm.nih.gov/19224580/)
Schiavo G, et al. (2013). "SMN and dynein." Nat Rev Neurosci. PMID: 24201256(https://pubmed.ncbi.nlm.nih.gov/24201256/)
Dynlt3 — Dynein Light Chain Tctex Type 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Dynlt3 — Dynein Light Chain Tctex Type 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Hafezparast M, et al, (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12947150/)
[Rao MV, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19224580/)
[Schiavo G, et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24201256/)